Clinical and Genetic Insights into Congenital Generalized Lipodystrophy Type 4: A Case Report

Area of Science:

• Genetics
• Endocrinology
• Rare Diseases

Background:

• Lipodystrophy syndromes (LS) are heterogeneous disorders of adipose tissue with significant metabolic complications.
• Congenital generalized lipodystrophy (CGL) is a rare form characterized by generalized loss of adipose tissue.
• Metabolic and hormonal derangements are key features impacting morbidity and mortality.

Purpose of the Study:

• To present a case of CGL type 4 with a novel combination of clinical findings.
• To highlight the genetic basis and associated complications of CGL type 4.
• To emphasize the importance of early genetic diagnosis for management.

Main Methods:

• Next-generation sequencing (NGS) for genetic analysis.
• Clinical assessment for lipodystrophy, myopathy, and associated morbidities.
• Monitoring of metabolic, hormonal, and cardiovascular parameters.

Main Results:

• Identification of a *CAVIN1* mutation in a patient with CGL type 4.
• Observed metabolic disorders (low leptin, vitamin D; insulin resistance) and hormonal disorders (low IGF-1, delayed puberty).
• Documented severe morbidities including osteoporosis, scoliosis, and cardiac arrhythmias, plus ultrarare cerebral artery hypoplasia.

Conclusions:

• CGL type 4 diagnosis should consider elevated liver enzymes and creatine phosphokinase.
• The co-occurrence of congenital generalized lipodystrophy type 4 and structural cerebral vascular anomalies is unprecedented.
• Genetic identification facilitates timely monitoring and treatment of CGL patients.